Close to 300 people gathered at The Globe and Mail Centre on November 14 to join a conversation on growth strategies for the Canadian biomedical sector.
Speakers agreed Canada punches above its weight in early-stage research and clinical trials but has yet to produce a home-grown, large-scale life sciences company.
“We’re investing in this early stage research. Where are the outputs? Where is our BlackBerry of biotech?” asked Jason Field, president of Life Sciences Ontario.